Stay updated with breaking news from Ben Har. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OpenWallet, now joined by Microsoft, looks to the near future when digital wallets replace traditional wallets in the same way debit cards replaced checkbooks.
Prilenia Therapeutics: Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO PROOF-HD is the most advanced clinical trial in HD assessing impact on clinical progression Dr. Y Paul Goldberg joins Prilenia to enhance the broader scientific strategy for pridopidine Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, is pleased to announce that it has now enrolled more than 120 patients in its Phase 3 trial of pridopidine in HD (PROOF-HD), reaching 25% of th...
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington's Disease About Prilenia (www.prilenia.com) Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders. Prilenia raised 88.5 million thus far and is backed by a group of well-respected investors: Talisman, Forbion, Morningside and Sectoral and ALS Investment Fund. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in t...
Press release content from Business Wire. The AP news staff was not involved in its creation. Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS January 8, 2021 GMT NAARDEN, The Netherlands--(BUSINESS WIRE)--Jan 8, 2021-- Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announces the enrollment of the first participant for treatment with pridopidine in the pivotal HEALEY ALS Platform Trial. The HEALEY ALS Platform trial (“HEALEY trial”; N...
(1) Pridopidine was chosen in global competition as one of the top drug candidates to participate in the first ever ALS Platform Trial led by the Healey Center at Massachusetts General Hospital This trial is the second late-stage clinical trial in neurodegenerative disorders with pridopidine, in addition to the global Phase 3 trial in Huntington's disease Positive data from this clinical study could lead to registration of pridopidine for the treatment of ALS Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodev...